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Idiopathic inflammatory myopathies are autoimmune diseases characterized by symmetrical proximal muscle weakness. Our
aim was to identify a correlation between VDR polymorphisms or haplotypes and myositis. We studied VDR-BsmI, VDR-ApaI,
VDR-TaqI, and VDR-FokI polymorphisms and haplotypes in 89 Hungarian poly-/dermatomyositis patients (69 females) and 93
controls (52 females). We did not obtain any significant differences for VDR-FokI, BsmI, ApaI, and TaqI genotypes and allele
frequencies between patients with myositis and healthy individuals.There was no association of VDR polymorphisms with clinical
manifestations and laboratory profiles inmyositis patients.Menwithmyositis had a significantly different distribution ofBB,Bb, and
bb genotypes than female patients, control male individuals, and the entire control group. Distribution of TT, Tt, and tt genotypes
was significantly different inmales than in females in patient group. According to four-marker haplotype prevalence, frequencies of
sixteen possible haplotypes showed significant differences between patient and control groups.The three most frequent haplotypes
in patients were the fbAt, FBaT, and fbAT. Our findings may reveal that there is a significant association: Bb and Tt genotypes can
be associated with myositis in the Hungarian population we studied. We underline the importance of our result in the estimated
prevalence of four-marker haplotypes.
1. Introduction
Idiopathic inflammatory myopathies (IIMs) are autoim-
mune diseases characterised by proximal symmetricalmuscle
weakness. Adult polymyositis (PM)/dermatomyositis (DM),
juvenile polymyositis (JPM)/dermatomyositis (JDM), over-
lap myositis (OM), inclusion body myositis (IBM), and
necrotizing autoimmunemyopathy (NAM) all belong to IIM.
According to one of the biggest analyses, in which forty-six
articles—published between 1966 and 2013—were searched,
the incidence of IIMs ranges from 1.16 to 19/million/year and
the prevalence ranges from 2.4 to 33.8/100000 inhabitants [1].
In this study authors found disparities in the male-female
ratio, according to geographical origin [1]. Our workgroup
previously found that the male-female ratio among three
hundred and thirty-sevenHungarian IIM patients was 1 : 2.92
[2]. Ethnical differences and HLA-associations suggest that
genetic factors also may play a part in the aetiology.
Vitamin D is essential for normal development and
maintenance of bones. It also impacts immunoregulation,
enhances the production of interleukin- (IL-) 1, and obstructs
the production of IL-2 [3, 4]. VitaminD is considered as a reg-
ulator of the immune system [5, 6]. Most biological activities
of vitamin D are mediated by the vitamin D receptor (VDR),
which is located in the nucleus [7]. VDR acts as a transcrip-
tion factor activated by a ligand and is encoded by the vitamin
D receptor gene [8].The VDR gene is located on chromosome
12 (12q12-q14) [9]. In recent years many polymorphisms have
been identified in the VDR gene, but their effects on VDR
activity are still poorly understood [10]. The VDR gene has
more than 100 restriction endonuclease recognition sites, but
only 4 of them are known polymorphisms: FokI, BsmI, ApaI,
and TaqI. FokI is located in exon II, while BsmI and ApaI
(in intron 8) and TaqI (in exon 9) have been identified at
the 3󸀠 end of the gene. The effects of vitamin D and the
VDR gene polymorphisms are in connection with each other.
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Nowadays, there is evidence that these polymorphisms have
a relationship to such diseases or conditions where vitamin
D has an essential role, for example, bone mineral density,
osteoporosis and cancers of the breast and prostate [11–13].
According to Ferrari et al. VDR gene allelic variants predict
bone mineral density and the effect of calcium intake on
maintenance of bone mass could relate to VDR gene pol-
ymorphisms [11]. A study from Iran lends support to an
increased risk of breast cancer associated with theVDR-BsmI
polymorphism [12]; one Chinese study says that VDR gene
polymorphisms may be potential risk factors for prostate
cancer [13].
The latest findings suggest that allelic variations of VDR
gene may partially represent a genetic component associated
with incidence, clinical symptoms, or severity of autoimmune
diseases or to the susceptibility of them [14–22]. It is notable
that none of these studies shows a causative relationship
between genes and disease development.
To the best of our knowledge, there is no information in
the literature about the VDR gene polymorphisms and their
association with myositis disease. Therefore the aim of this
studywas to determinewhether an association exists between
VDR gene polymorphisms and IIM. We assessed the VDR
gene BsmI, ApaI, TaqI, and FokI polymorphisms in patients
with IIM and healthy controls to assess whether a relationship
exists between polymorphisms/haplotypes in the VDR gene
and susceptibility to PM/DM. Our aim was also to identify
whether an association exists between VDR gene poly-
morphisms and some significant markers of myositis: the
phenotype of disease, age at disease onset, gender, the pre-
sence of myositis-specific autoantibodies, or the presence of
osteoporosis. BsmI, ApaI, and TaqI have been shown to be
in strong linkage disequilibrium (LD) [23]. LD means that
there is an association of alleles of adjacent polymorphisms
with each other. LD in combination with one or more
functional polymorphisms elsewhere inVDRgene is believed
to explain the observed associations between the VDR gene
and diseases. Another aim of the study was to establish
haplotype analysis, which has recently become important due
to newly developed field of bioinformatics.
2. Methods
2.1. Patients and Controls. 89 patients with IIMwere enrolled
in the present study, recruited from the Autoimmune Out-
patient Clinic of the Department of Clinical Immunology,
Medical Faculty, University of Debrecen. The patient group
included 69 female and 20 male patients; male-female ratio
was 1 : 3.45; this is similar to our previous results [2]. The
mean age was 52.6, ranging from 9 to 81 years. One limitation
of the study is that the patient cohort was very heterogeneous
because of diseases with different pathogenesis. The distri-
bution of IIM patients was as follows: PM, 𝑛 = 46; DM,
𝑛 = 15; JPM/JDM, 𝑛 = 9; OM, 𝑛 = 17 (myositis and RA in
10 patients; myositis and progressive systemic sclerosis (PSS)
in 5 patients; myositis and mixed connective tissue disease
(MCTD) in 2 patients); NAM, 𝑛 = 1; IBM, 𝑛 = 1. The
diagnosis of PM and DM was established according to the
criteria determined by Bohan and Peter [24]: (1) symmetrical
proximalmuscleweakness, (2) positivemuscle biopsy, (3) ele-
vation of serum skeletal muscle enzymes, (4) myopathic triad
on electromyography, and (5) characteristic skin symptoms
(Gottron’s signs, Gottron’s papules, V-sign, scarf sign, erythe-
matous rashes, heliotrope rash, periungual capillary changes,
and periorbital oedema) in DM. The diagnosis of JPM and
JDM was established when the first symptoms of myositis
developedunder the age of eighteen. In the case ofOMmyosi-
tis occurred together with other connective tissue diseases
(CTDs) such as RA, PSS, or MCTD. It has to be laid down
that the Bohan and Peter criteria aremainly employed to refer
to PM and DM. That is why the Hilton-Jones MRC criteria
have to be used for IBM which is a late onset myopathy
with both inflammatory and myodegenerative features [25].
NAM patients present with a subacute severe symmetrical
proximal myopathy, associated with a markedly elevated
creatine kinase level. NAM patients must have the common
histopathological features ofmyocyte necrosis without signif-
icant inflammation [26].
A total of 93 healthy individuals (mean age 41.2 years,
range 14 to 70 years, 52 females and 41 males) taking no
immunosuppressive or immunomodulating medications
served as the control group.
Informed consent was obtained from all of the subjects.
All experiments carried out were in compliance with the
Declaration of Helsinki.
2.2. Detection of Myositis-Specific Autoantibodies (Anti-Jo-1,
Anti-PL-7, Anti-PL-12, Anti-Mi-2, and Anti-SRP). These anti-
bodies were detected by membrane-fixed immunoblot
(Orgentec Diagnostika). The method is briefly described.
First, the contents of each vial of buffered wash solution
concentrate were dilutedwith distilled water to a final volume
of 1000mL prior to use. A myositis plus strip was inserted
and 1mL of sample buffer was added to each chamber of
the incubation tray. Then, it was equilibrated for 5min with
gentle rocking. 10 𝜇L of sera was added to each chamber and
incubated for 60min at room temperature. Then, the diluted
serum was removed from the strips. 2mL of wash buffer was
added; it was incubated for 5min and then removed. This
procedure had to be repeated twice. 1.0mL of the enzyme
conjugate was added to each chamber and incubated for
30min. After removing the diluted conjugate, 2.0mL of wash
buffer was added and it was incubated for 5min; then, it was
removed and this step was repeated further two times. After
adding 1mL of substrate to each strip, a 10min incubation
was performed and, after removing the substrate, it was
washed with 1mL of distilled water, three times [27].
2.3. Detection Myositis-Associated Antibodies. Enzyme-linked
immunosorbent assay (ELISA) was used for the detection
of the following myositis-associated antibodies: rheumatoid
factor (RF), anticyclic citrullinated peptide (anti-CCP), and
anti-dsDNA (anti-double-strand deoxyribonucleic acid).
Anti-Ku, anti-PM-Scl, anti-U1RNP, anti-SSA, and anti-
SSB were detected with immunoblot.
2.4. Detection of Extramuscular Manifestations in Myositis
Patients. The presence of cardiac involvement (myocarditis
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Table 1: Sequences of specific primers and the profile of PCR used to amplify the DNA fragment carrying FokI,ApaI, and TaqI SNPs [28, 29].
FokI polymorphism (rs2228570) ApaI and TaqI polymorphisms (rs7975232 and rs731236)
Primers 5
󸀠-AGC TGG CCC TGG CAC TGA CTC TGC TCT-3󸀠 5󸀠-CAG AGC ATG GAC AGG GAG CAA G-3󸀠
5󸀠-ATG GAA ACA CCT TGC TTC TTC TCC CTC-3󸀠 5󸀠-GCA ACT CCT CAT GGC TGA GGT CTC A-3󸀠
PCR conditions
(40 cycles)
30 sec at 95∘C 30 sec at 94∘C
30 sec at 70∘C 1min at 70∘C
30 sec at 72∘C 1min at 72∘C
Length of PCR
product (bp) 265 740
and pericarditis) was investigated by echocardiography. The
gastrointestinal disease activity was checked by asking the
patient about the presence of dysphagia. Every singlemyositis
patient’s thorax was controlled by high resolution computer
tomography and the diffusing capacity of the lung for carbon
monoxide (DLCO). These are useful in judgment of the
presence of interstitial lung disease. Arthritis was detected by
physical examination and by X-ray.
2.5. Genomic DNA Extraction. Genomic DNA for genotyp-
ing was extracted from peripheral blood, which was col-
lected in EDTA vacutainers. Genomic DNA was extracted
according to the manufacturer’s recommendation using a
QiaAmp DNA Blood Mini Kit (Qiagen GmbH, Germany).
2.6. DNA Quantification. DNA was quantitated by UV
absorption at 260 nm and 280 nm and stored at −20∘C until
analysed.
2.7. Genotyping of the BsmI Polymorphism (rs1544410).
Genotyping of the BsmI polymorphism was carried out in
PCR-amplified DNA by allelic discrimination using TaqMan
from Applied Biosystems (Foster City, CA, USA). PCR
primers and TaqMan probes specific for the BsmI polymor-
phism were purchased from Applied Biosystems. The assay
enables scoring of both alleles in a single well. Real-time
PCR was performed using Corbett Rotor-Gene RG-3000
equipment.
The PCR reaction was carried out in a 20 𝜇L reaction vol-
ume containing TaqMan Universal Master Mix (2x, Applied
Biosystems), TaqMan genotyping assay (40x), and optimised
quantities of genomic DNA. The Universal Master Mix con-
tained AmpliTaq Gold DNA polymerase, AmpErase UNG,
dNTPs with dUTP, passive reference, and optimised buffer
components. Reactions were set up in duplicate. Thermal
cyclingwas initiated by incubation at 95∘C for 10min for opti-
mal AmpErase UNG activity and the activation of Amplitaq
Gold DNA polymerase. After this initial step, 40 cycles of
PCR were performed; each PCR cycle consisted of heating to
92∘C for 15 sec for denaturation of the DNA and then cooling
to 60∘C for 1min for annealing and extension.
2.8. Genotyping of FokI, ApaI, and TaqI Polymorphisms. The
genotypes of the VDR gene FokI, ApaI, and TaqI polymor-
phisms were determined according to the digestion pattern
generated for the amplified DNA fragment using the restric-
tion enzymes FokI, ApaI, and TaqI.
2.8.1. FokI Polymorphism (rs2228570). Genotypes for the
FokI polymorphisms were studied by PCR using the primers
described in Table 1 [28]. PCR products were amplified in
a programmable thermal cycler (Eppendorf-MC-EP model).
The PCR conditions used to amplify the FokI SNP are
summarised in Table 1. The amplified products were digested
by incubation with the FokI enzyme (Fermentas Life Sci-
ences) for 1 hour at 37∘C, according to the manufacturer’s
instructions; products were electrophoresed on a 3% agarose
gel and visualised by SYBR Green I staining. FokI genotypes
were defined by capital letters in the absence of the restriction
site (allele-F) and lowercase letters where the restriction site
was present (allele-f ).
2.8.2. ApaI and TaqI Polymorphisms (rs7975232 and rs731236).
Genotypes for the ApaI and TaqI polymorphisms were
studied by PCR using the primers as described in Table 1
[29]. The PCR conditions to amplify the ApaI and FokI SNPs
are summarised in Table 1. The PCR products were digested
by incubation with ApaI (Fermentas Life Sciences) for 4
hours at 37∘C and TaqI (Fermentas Life Science) for 1 hour
at 60∘C. After digestion, the fragments were separated by
electrophoresis in 3% agarose gels and visualised by SYBR
Green I staining. For both ApaI and TaqI, genotypes were
defined by capital letters in the absence of the restriction site
(A and T, resp.) and lowercase letters where the restriction
site was present (a and 𝑡, resp.).
2.9. Statistical Analysis. Genotype frequencies were calcu-
lated by direct counting. Allele frequencies were calculated
from genotype frequencies based upon Hardy-Weinberg
equilibrium. For comparisons of mean values between
patients and controls, statistical analysis was performed using
the independent samples 𝑡-test. Differences in genotypic and
allelic distribution of VDR polymorphisms between patients
and controls were determined by Pearson Chi-square (𝜒2)
test using SPSS 20.0 statistical software. The 𝑃 value less
than .05 was regarded as statistically significant. Haplotype
analysis was performed by CHAPLIN 1.2 software. Pairwise
linkage disequilibrium (LD) between theVDRgene polymor-
phisms was computed, and LD plots were constructed using
Haploview software, version 4.2 [30].
3. Results
We studied VDR-BsmI, VDR-ApaI, VDR-TaqI, and VDR-
FokI polymorphisms in 89 polymyositis/dermatomyositis
patients and 93 healthy controls.
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Table 2: Distribution of VDR-FokI, VDR-BsmI, VDR-TaqI, and VDR-ApaI genotypes in our Hungarian cases and controls.
Enzyme analysis IIM patients(89 patients)










BB 19,1% 18,37% 8,69% 35,3% 15,9%
Bb 39,33% 36,73% 47,83% 35,3% 46,2%
bb 41,57% 44,9% 43,48% 29,4% 37,8%
Allele frequencies
B 0,387 0,367 0,326 0,529 0,39
b 0,612 0,633 0,674 0,471 0,61
ApaI polymorphism
Genotypes
AA 37,07% 34,69% 30,43% 52,94% 24,73%
Aa 39,33% 38,78% 52,17% 23,53% 50,54%
aa 23,6% 26,53% 17,4% 23,53% 24,73%
Allele frequencies
A 0,567 0,541 0,565 0,647 0,5
a 0,433 0,459 0,435 0,353 0,5
TaqI polymorphism
Genotypes
TT 43,82% 51,02% 34,78% 35,3% 40,86%
Tt 37,08% 28,57% 52,18% 41,17% 39,79%
tt 19,1% 20,41% 13,04% 23,53% 19,35%
Allele frequencies
T 0,623 0,653 0,609 0,559 0,61
t 0,376 0,347 0,391 0,441 0,39
FokI polymorphism
Genotypes
FF 26,97% 30,61% 21,74% 23,53% 42,25%
Ff 48,31% 42,86% 52,17% 58,82% 43,66%
ff 24,72% 26,53% 26,09% 17,65% 14,08%
Allele frequencies
F 0,511 0,52 0,478 0,529 0,64
f 0,489 0,48 0,522 0,471 0,36
3.1. Allele Frequencies of VDR Gene Polymorphisms in IIM
Patients. The distribution of allelic frequencies for the four
polymorphisms studied here is summarised in Table 2. The
characteristics are shown separately for threemain phenotype
groups: (1) PM (including one patient with JPM, one patient
with IBM, and one patient with NAM); (2) DM (including 8
patients with JDM); and (3) overlap patients. No significant
difference was found for allele frequencies when data were
compared between patients with IIM and control individuals.
We identified a difference in the frequency of F and f alleles
between the IIM population and the control population, but
this was not significant. In addition, no significant difference
was observedwhen the IIMcaseswere grouped into PM,DM,
and overlap cases.
3.2. Genotype Frequencies of VDR Gene Polymorphisms in
IIM Patients. No significant difference was found in the
genotype frequencies when the VDR gene genotypes of
patients with IIM and healthy individuals were compared
(Table 2). The same result was confirmed between PM, DM,
and overlap cases (Table 2). However, we detected slightly
increased prevalence of the AA genotype in IIM patients
compared with controls: 37.07% versus 24.73%, respectively.
The frequency of Aa genotype was slightly decreased in IIM
patients compared with the control population: 39.33% and
50.54%, respectively. Some other notable differences were
as follows: (a) the TT genotype was more frequent in PM
patients than in DM patients (51.02% versus 34.78%, resp.);
(b) the Tt genotype was less frequent in patients with PM
than patients with DM (28.57% versus 52.18%, resp.); (c) the
frequency of the FF genotype was lower in IIM patients than
in controls: 26.97% versus 42.25%, respectively.
The patients were classified into groups according to their
gender, age at disease onset, laboratory profiles (myositis-
specific andmyositis-associated autoantibody positivity), and
the presence of osteoporosis. The most important clinical
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Table 3: The distribution of various genotypes in our Hungarian myositis patients and healthy individuals (representing the cases with a 𝑃
value less than .05).
BB Bb bb
Number of male myositis patients 1 15 4
𝑃 value < .001
Number of female myositis patients 16 20 33
BB Bb bb
Number of male myositis patients 1 15 4
𝑃 value = .0323
Number of control individuals 16 40 37
BB Bb bb
Number of male myositis patients 1 15 4
𝑃 value = .0176
Number of control male individuals 8 15 18
TT Tt tt
Number of male myositis patients 5 12 3
𝑃 value = .037
Number of female myositis patients 34 20 15
FF Ff ff
Number of MAA positive patients 2 14 5
𝑃 value = .0033
Number of control individuals 31 33 29
AA Aa aa
Number of female myositis patients 28 23 18
𝑃 value = .0398
Number of control female individuals 11 28 13
manifestations that are of great importance to the prognosis
of IIM were also investigated. These are the following extra-
muscularmanifestations: the presence of cardiac involvement
(myocarditis), esophagus involvement (dysphagia), other
skeletal involvements (arthralgia, arthritis), and lung involve-
ment (interstitial lung disease). There was no association of
VDR gene polymorphisms with clinical manifestations in
IIM patients.
We detected important associations when investigating
gender. The statistical 𝑡-test showed significant differences
as follows: the distribution of BB, Bb, and bb genotypes was
found to be significantly different (𝑃 < .001) in males com-
pared to females among myositis patients (Table 3). We also
found a similar distribution for VDR-TaqI polymorphism.
The distribution of TT, Tt, and tt genotypes was significantly
different (𝑃 = .037) in male myositis patients than in
female myositis patients, as shown in Table 3. We also found
statistically significant differences as follows: (a) comparing
the male myositis patients with the entire control group, we
established that the distribution of BB, Bb, and bb genotypes
was significantly different (𝑃 = .0323) in the male IIM
patients, (b) the distribution of the BB-Bb-bb genotype in the
male patient group versus the men in the control group also
showed a significant difference (𝑃 = .0176), (c) significant
difference was detectable when comparing the frequency
of FF, Ff, and ff genotypes between myositis-associated
autoantibody positive patients and the control population
(𝑃 = .0033), and (d) when examining the distribution of AA,
Aa, and aa genotypes in female myositis patients and control
female patients, the 𝑃 value was .0398 (Table 3). Finally,
comparing the distribution of AA, Aa, and aa genotypes
between myositis patients with other autoimmune disease
(overlap cases) and controls the 𝑃 value was found to be .054.
3.3. Linkage Disequilibrium and Haplotype Frequencies of
VDR Gene Polymorphisms in IIM Patients. The haplotypes
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Frequency in IIM patients (%)
Frequency in healty individuals (%)
Figure 1: Three-marker (BsmI, ApaI, and TaqI polymorphisms)
haplotype estimated prevalence (%) in IIM patients and healthy
individuals (IIM: idiopathic inflammatory myopathy).
often able. The calculated haplotype frequencies for VDR-
BsmI, VDR-ApaI, and VDR-TaqI polymorphisms of the IIM
patients and controls are shown in Figure 1. There was no
significant difference in the calculated haplotype frequencies
between the control and the patient groups. The baT and
the BAt haplotypes were the most frequent in both the
patient group (35.22% and 30.28%, resp.) and the control
population (48.35% and 31.46%, resp.). bAT haplotype was
not as frequent as the above-mentioned haplotypes but was
also frequent in both groups (19.33% in patients versus 10.16%
in healthy population). The combined frequency of the five
remaining haplotypes was less than 10%. The Bat was not




































Frequency in IIM patients (%)
Frequency in healthy individuals (%)
Figure 2: Four-marker (FokI; BsmI; ApaI; and TaqI polymor-
phisms) haplotype estimated prevalence (%) in IIM patients and
healthy individuals (IIM: idiopathic inflammatory myopathy).
present in the patient group, and in the control group, the
estimated frequency of BaT was 0%.
The distribution of the frequency of four-marker haplo-
type alleles (VDR-FokI, VDR-BsmI, VDR-ApaI, and VDR-
TaqI) in IIM cases and controls is shown in Figure 2.
According to the diagram, there are significant variances in
the distribution.Themost frequent haplotype in IIM patients
was the fbAt haplotype (19.07%); the estimated prevalence of
this haplotype in controls was only 1.41%. The second and
third most frequent ones in patients were FBaT and fbAT
(18.18% and 16.25%, resp.), while the estimated prevalence
in the control group was only 0% and 1.34%, respectively.
We should highlight here that, according to our findings,
the three most frequent four-marker haplotypes in healthy
individuals were as follows: FbaT (29.78%), fbaT (24.50%),
and FBAt (22.59%). The estimated frequency of these in
patients was 0%, 3.61%, and 0%, respectively.
LD analysis revealed a very strong LD (𝑟2 > .8) between
ApaI and TaqI polymorphisms, a strong LD (𝑟2 between .67
and .7) between BsmI and ApaI or BsmI and TaqI polymor-
phisms, and a very weak LD (𝑟2 < .3) between FokI and other
polymorphisms in the control group. In patients, very strong
LD was found between BsmI and ApaI polymorphisms;
moderate LD was found between TaqI-ApaI and TaqI-BsmI
polymorphisms. No LD was observed between FokI and
other polymorphisms in patients (Figure 3).
4. Discussion
VDR gene polymorphisms have been identified and analyzed
so far in a wide variety of diseases, including Parkinson
disease, cancer of the breast, and autoimmune diseases [23, 31,
32].There are many workgroups from the Far East that inves-


























































Figure 3: Four common gene polymorphisms of linkage disequi-
librium of VDR gene of IIM patients (a) and the healthy controls
(b). Graphical presentation of the VDR gene with the location
of polymorphisms studied. Numbers in the boxes represent the
correlation coefficient value of linkage disequilibrium (𝑟2) value
multiplied by 100. The intensity of the dark color of the boxes
represents strength of linkage disequilibrium (𝑟2) with dark boxes
having high LD and white boxes having low LD. (LD: linkage
disequilibrium).
an association between Aabb genotypes and the incidence
of systemic lupus erythematosus (SLE); Aabb was involved
in some clinical conditions and in antibody-production [14].
Results of another Chinese study indicated a possible role of
the B allele in influencing SLE susceptibility [15]. By multiple
sclerosis (MS) the results are controversial. Some articles
[16, 17] neglect any association of VDR gene polymorphisms
with disease susceptibility; however a Russian article refers
to different clinical manifestations [18]. VDR polymorphisms
may contribute to the high prevalence of RA in North
American natives [19]. A Polish study said that BsmI may
show some correlation with RA activity and progression [20].
According to an article from Spain bb genotype is associated
with less severe disease [21].There is some information about
the VDR polymorphisms and the autoimmune thyroid dis-
eases (AITD), as well [22]. One limitation of the mentioned
studies is that they were carried out in different countries,
preeminently in the Far East; they are distinct populations
and the comparison with Central European data is not
suitable.
TheCentral European literature about the possible associ-
ation of VDR gene polymorphisms and autoimmune diseases
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is very limited. To the best of our knowledge there is no
information in the literature aboutVDRgene polymorphisms
and their connection with myositis. In our study, we deter-
mined VDR gene BsmI,ApaI, TaqI, and FokI polymorphisms
in patients with IIM and healthy controls to analyse whether a
relationship exists between the polymorphisms/haplotypes in
VDRgene and susceptibility to PM/DM.Ourmost important
findings were connected to the VDR-BsmI polymorphism,
VDR-TaqI polymorphism, and male gender. Based on our
data, we can state that the distribution of BB, Bb, and bb
genotypes represents an interesting finding because BB and
bb genotypes were presented at a very low percentage in
the male patient population. The distribution of TT, Tt,
and tt genotypes was significantly different in males than in
females in the patient group. Our findings may reveal that
IIM can be associated with the Bb genotype of the VDR-
BsmI polymorphism and the Tt genotype of the VDR-TaqI
polymorphism in males in our cohort.
As mentioned before, Hitchon et al. [19] found that RA
is associated with the FokI polymorphism of the VDR gene.
In our case-control study, 17 patients were included with
OM, and 10 of these had RA. Comparing the distribution of
FF, Ff, and ff genotypes of the VDR gene identified a sig-
nificant difference betweenmyositis-associated autoantibody
positive patients and the control population.The Ff genotype
was found to be the most frequent genotype in myositis-
associated antibody positive cases (66.67% out of the positive
patients). Also, 42.86%of theMAApatientswereRF-positive,
which confirms the results reported by Hitchon et al. [19].
The baT and BAt haplotypes were found to be the most
frequent three-marker haplotypes in both the patient and
control groups. These three-marker haplotypes were identi-
fied as the most frequent and corresponded to haplotypes
reported by Morrison et al. [33].
Our data demonstrated that the frequencies of the sixteen
possible haplotypes showed significant differences between
the patient and the control groupswhen the four-marker hap-
lotype prevalence was assessed. Several differences that were
not statistically significant might accumulate and recombine
in individuals resulting in significant differences in the level
of four-marker haplotypes. This is the reason why certain
haplotypes are represented in patients but are not found in
control individuals according to the statistical calculations
(Table 2 and Figure 2).
5. Conclusions
This is the first study to investigate the four known poly-
morphisms (FokI, BsmI, ApaI, and TaqI polymorphisms)
in the VDR gene in patients with IIM. We found that a
relationship may exist between the BsmI genotype and IIM
in males and TaqI genotype and IIM in males as well. The
most important limitation of the study is that our cohort was
small. Males’ number is limited to twenty, so we cannot claim
certain assessments about the difference in polymorphisms
prevalence in males and women.
In our study, we identified an important difference in the
estimated prevalence (%) of the four-marker (FokI; BsmI;
ApaI; and TaqI polymorphisms) haplotypes between IIM
patients and healthy individuals. The three most frequent
haplotypes in patients were the fbAt, FBaT, and fbAT, while
this ranking in the control group was as follows: FbaT, fbaT,
and FBAt. The pathomechanism of IIM is still unclear, but
the genetic predisposition and environmental conditions play
an important role. According to our findings, the genotype
variations of the VDR gene polymorphisms may be one of
the factors in the development of IIM which is a polygenic
and multifactorial autoimmune disease.
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